Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
Oncology biotech focused on targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers Results expected Sep 2026 (estimated)
- New drug cocktail targets Hard-to-Treat lung cancer mutation Results expected Sep 2026 (estimated)
- Lung cancer drug adagrasib: which dose works best? Results expected Oct 2026 (estimated)
-
Lung cancer drug adagrasib: which dose works best?
Disease control OngoingThis phase 2 study compares two dosing schedules of the targeted drug adagrasib (Krazati) in 200 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried chemotherapy and immunotherapy. The goal is to see if a lower d…
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
Disease control OngoingThis phase 3 trial is comparing an experimental targeted drug called adagrasib (MRTX849) with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has already been treated. The study aims to see if adagr…
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a drug called adagrasib (MRTX849) in people with advanced solid tumors that have a specific genetic mutation called KRAS G12C. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 731 participants with various…
Phase 1/2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control OngoingThis phase 3 trial tests whether a new targeted drug (MRTX849) combined with cetuximab works better than standard chemotherapy for people with advanced colorectal cancer that has a specific KRAS G12C mutation. About 461 participants whose cancer worsened after first-line treatmen…
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer mutation
Disease control OngoingThis phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC